Search research articles
Contact Us
Filters
Showing results (71-80 of 218) with videos related to
Page
of 22
Sort By:
JCO Precision Oncology
|
February 17, 2022
Trametinib-Induced Remission of an <i>MEK1</i>-Mutated Langerhans Cell Histiocytosis
Matina Papapanagiotou, Klaus G Griewank, Uwe Hillen, et al.
Frontiers in Oncology
|
August 30, 2021
Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition - Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry
Jan-Malte Placke, Josefine Rawitzer, Henning Reis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 13, 2024
The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations
Katrin Schaper-Gerhardt, Ralf Gutzmer, Yenny Angela, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society
|
February 6, 2022
Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma
Justin Ferdinandus, Anne Zaremba, Lisa Zimmer, et al.
Journal for Immunotherapy of Cancer
|
May 31, 2019
Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
Anne Zaremba, Eleftheria Chorti, Finja Jockenhöfer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 6, 2020
Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis
Eleftheria Chorti, Theodora Kanaki, Lisa Zimmer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 27, 2026
Multi-modal computational data analysis for prediction of response to systemic treatment in metastatic melanoma
Vicky Parmar, Georg Lodde, Johannes Haubold, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 20, 2017
Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
Ralf Gutzmer, Anika Koop, Friedegund Meier, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 3, 2021
Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma
Justin Ferdinandus, Wolfgang P Fendler, Katharina Lueckerath, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
January 3, 2025
Real-world management of patients with complete response under immune-checkpoint inhibition for advanced melanoma
Markus Reitmajer, Elisabeth Livingstone, Kai-Martin Thoms, et al.
Page
of 22
Search research articles
Search
Showing results (71-80 of 218) with videos related to
Sort By:
Page
of 22
JCO Precision Oncology
|
February 17, 2022
Trametinib-Induced Remission of an <i>MEK1</i>-Mutated Langerhans Cell Histiocytosis
Matina Papapanagiotou, Klaus G Griewank, Uwe Hillen, et al.
Frontiers in Oncology
|
August 30, 2021
Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition - Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry
Jan-Malte Placke, Josefine Rawitzer, Henning Reis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 13, 2024
The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations
Katrin Schaper-Gerhardt, Ralf Gutzmer, Yenny Angela, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society
|
February 6, 2022
Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma
Justin Ferdinandus, Anne Zaremba, Lisa Zimmer, et al.
Journal for Immunotherapy of Cancer
|
May 31, 2019
Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
Anne Zaremba, Eleftheria Chorti, Finja Jockenhöfer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 6, 2020
Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis
Eleftheria Chorti, Theodora Kanaki, Lisa Zimmer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 27, 2026
Multi-modal computational data analysis for prediction of response to systemic treatment in metastatic melanoma
Vicky Parmar, Georg Lodde, Johannes Haubold, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 20, 2017
Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
Ralf Gutzmer, Anika Koop, Friedegund Meier, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 3, 2021
Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma
Justin Ferdinandus, Wolfgang P Fendler, Katharina Lueckerath, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
January 3, 2025
Real-world management of patients with complete response under immune-checkpoint inhibition for advanced melanoma
Markus Reitmajer, Elisabeth Livingstone, Kai-Martin Thoms, et al.
Page
of 22